NDATOPICALOINTMENT
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
18/100
Mechanism of Action
phosphodiesterase-4 (PDE-4). Difamilast's inhibition of PDE-4 (a major cyclic adenosine monophosphate (AMP)-metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP and decreased productions of various cytokines and chemokines. However, the specific mechanism(s) by which…
Indications (1)
Loss of Exclusivity
LOE Date
Feb 12, 2031
60 months away
Exclusivity Expiry
Feb 12, 2031
External Resources